Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals

L Collette, T Burzykowski, KJ Carroll, D Newling, T Morris, Fritz Schröder

Research output: Contribution to journalArticleAcademicpeer-review

103 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)6139-6148
Number of pages10
JournalJournal of Clinical Oncology
Volume23
Issue number25
Publication statusPublished - 2005

Cite this